A major contributor to the lack of medicines in developing countries is an intellectual property regime that allows proprietary drug companies with intellectual property monopolies to charge high prices and maximize profit.
Dr Esha Bansal joins Ethics Talk to discuss her article, coauthored with Drs Saran Kunaprayoon and Linda P. Zhang: “Opportunities for Global Health Diplomacy in Transnational Robotic Telesurgery.”
Eitan Neidich, Alon B. Neidich, David A. Axelrod, MD, and John P. Roberts, MD
Geographic disparities in availability of organs for transplant have spawned for-profit companies that help patients get on waitlists in more than one region and arrange travel for them if an organ becomes available.
Physicians who choose rural practice are called upon to deliver care that they have limited experience with, most notably in emergency situations when they are the most skilled people around.
This month, AMA Journal of Ethics theme editor Nikhil A. Patel, MS, a fourth-year medical student at the Mayo Medical School, interviewed Joia Mukherjee, MD, MPH, about Partners In Health’s mission to strengthen low-income countries’ health care systems and lessons learned from the Ebola crisis.
The United States government’s insistence that organs can only be procured through altruism, rather than being exchanged or purchased, contributes to the very exploitation of people of color in developing countries it sought to prevent.